Funding
Funding not disclosed
Founders
Product
Problem
Many cancers overexpress the MUC1-C oncoprotein, which drives tumor growth and resistance to therapy. Current cancer treatments often fail to specifically target MUC1-C, leading to off-target effects and limited efficacy. Additionally, hormonal imbalances like hypogonadism and hypothyroidism lack precise diagnostic tools and targeted treatments.
Solution
XYone Therapeutics is developing first-in-class therapeutics that target the MUC1-C oncoprotein to selectively inhibit cancer cell growth and overcome treatment resistance. Their approach involves novel agents designed to bind to and disrupt the function of MUC1-C, leading to targeted cancer cell death. XYone is also creating innovative diagnostic assays and formulations for hormonal imbalances, such as hypogonadism and hypothyroidism, to improve the accuracy of hormone measurements and enable more effective, personalized treatment strategies. These advancements aim to provide more precise and effective therapies for both cancer and endocrine disorders.
Target Audience
The primary target audience includes patients with cancers that overexpress the MUC1-C oncoprotein, as well as individuals suffering from hormonal imbalances such as hypogonadism and hypothyroidism.
Features
- Development of first-in-class agents targeting the MUC1-C oncoprotein
- Novel antibody-drug conjugates (ADCs) designed to selectively target and eliminate cancer cells expressing MUC1-C
- Diagnostic assays for precise measurement of hormone levels in patients with endocrine disorders
- Formulations designed to improve the delivery and efficacy of hormone replacement therapies
- Scientific publications and research projects focused on personalized patient care